The results revealed defective MSH2 and MSH6 in the tumor nuclei of III-14 and III-18, whereas only MSH2 was defective in tumor nuclei of III-15 (Figure 3), thus confirming the dMMR status in III-14, III-15, and III-18. This evidence concerns the gene MSH2 and neoplasm.